Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Akamata, Kaname ^a   Asano, Yoshihide ^a   Aozasa, Naohiko ^a   Noda, Shinji ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BLEOMYCIN; BOSENTAN; COLLAGEN; COLLAGEN 1 A2; COLLAGEN TYPE 1; DNA; ENDOTHELIN 1; MESSENGER RNA; PROTEIN; PROTEIN KINASE C DELTA; THREONINE; TRANSCRIPTION FACTOR FLI 1; UNCLASSIFIED DRUG; ENDOTHELIN RECEPTOR ANTAGONIST; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA BINDING; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PHENOTYPE; PRECIPITATION; PROMOTER REGION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; FIBROSIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CHROMATIN IMMUNOPRECIPITATION; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELIN-1; FIBROBLASTS; FIBROSIS; HUMANS; IMMUNOBLOTTING; MICE; PHENOTYPE; PROTO-ONCOGENE PROTEIN C-FLI-1; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; SULFONAMIDES;

EID: 84899144454     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4529     Document Type: Article

References (59)

1. Asano Y. Future treatments in systemic sclerosis. J Dermatol 2010, 37:54-70. 10.1111/j.1346-8138.2009.00758.x, 20175840.
2. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Increased expression levels of integrin αVβ5 on scleroderma fibroblasts. Am J Pathol 2004, 164:1275-1292. 10.1016/S0002-9440(10)63215-4, 1615355, 15039216.
3. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Increased expression of integrin αVβ3 contributes to the establishment of autocrine TGF-β signaling in scleroderma fibroblasts. J Immunol 2005, 175:7708-7718.
4. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Involvement of αVβ5 integrin-mediated activation of latent transforming growth factor β1 in autocrine transforming growth factor β signaling in systemic sclerosis fibroblasts. Arthritis Rheum 2005, 52:2897-2905. 10.1002/art.21246, 16142753.
5. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K. Increased expression of integrin αVβ5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 2006, 168:499-510. 10.2353/ajpath.2006.041306, 1606497, 16436664.
6. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Constitutive thrombospondin-1 overexpression contributes to autocrine transforming growth factor-β signaling in cultured scleroderma fibroblasts. Am J Pathol 2005, 166:1451-1463. 10.1016/S0002-9440(10)62362-0, 1606399, 15855645.
7. Varga J, Pasche B. Transforming growth factor β as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009, 5:200-206. 10.1038/nrrheum.2009.26, 3959159, 19337284.
8. Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, Pearson JD, Dashwood M, du Bois RM, Black CM, Leask A, Abraham DJ. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004, 15:2707-2719. 10.1091/mbc.E03-12-0902, 420095, 15047866.
9. Shi-Wen X, Rodríguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, Dashwood MR, du Bois RM, Denton CP, Black CM, Abraham DJ, Leask A. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 2006, 26:5518-5527. 10.1128/MCB.00625-06, 1592704, 16809784.
10. Shi-Wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD, Bou-Gharios G, Dashwood MR, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A. Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 2007, 26:625-632. 10.1016/j.matbio.2007.06.003, 17681742.
11. Shi-wen X, Kennedy L, Renzoni EA, Bou-Gharios G, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A. Endothelin is a downstream mediator of profibrotic responses to transforming growth factor b in human lung fibroblasts. Arthritis Rheum 2007, 56:4189-4194. 10.1002/art.23134, 18050250.
12. Lagares D, García-Fernández RA, Jiménez CL, Magán-Marchal N, Busnadiego O, Lamas S, Rodríguez-Pascual F. Endothelin 1 contributes to the effect of transforming growth factor b1 on wound repair and skin fibrosis. Arthritis Rheum 2010, 62:878-889. 10.1002/art.27307, 20131241.
13. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, Kashiwagi H. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992, 19:1566-1571.
14. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?. J Rheumatol 1994, 21:1838-1844.
15. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, Rich E, Carpentier P, Molitor J, Seibold JR, Hsu V, Guillevin L, Chatterjee S, Peter HH, Coppock J, Herrick A, Merkel PA, Simms R, Denton CP, Frust D, Nguyen N, Gaitonde M, Black C. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985-3993. 10.1002/art.20676, 15593188.
16. Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, Wigley FM, Black CM, Fessler BJ, Merkel PA, Pope JE, Sweiss NJ, Doyle MK, Hellmich B, Medsger TA, Morganti A, Kramer F, Korn JH, Seibold JR. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011, 70:32-38. 3002766, 20805294.
17. Denton CP, Humbert M, Rubin L, Black CM. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006, 65:1336-1340. 1798307, 16793845.
18. McLaughlin VV. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan. Eur J Clin Invest 2006, 36:10-15. 10.1111/j.1365-2362.2006.01688.x, 16919005.
19. Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006, 92:926-932. 10.1136/hrt.2005.069484, 1860719, 16339813.
20. Seibold JR, Denton CP, Furst DE, Guillevin L, Rubin LJ, Wells A, Matucci Cerinic M, Riemekasten G, Emery P, Chadha-Boreham H, Charef P, Roux S, Black CM. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010, 62:2101-2108.
21. Furuya Y, Kuwana M. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study. J Rheumatol 2011, 38:2186-2192. 10.3899/jrheum.110499, 21885489.
22. Iglarz M, Binkert C, Morrison K, Fischli W, Gatfield J, Treiber A, Weller T, Bolli MH, Boss C, Buchmann S, Capeleto B, Hess P, Qiu C, Clozel M. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008, 327:736-745. 10.1124/jpet.108.142976, 18780830.
23. Asano Y, Trojanowska M. Phosphorylation of Fli1 at threonine 312 by protein kinase C δ promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor β. Mol Cell Biol 2009, 29:1882-1894. 10.1128/MCB.01320-08, 2655609, 19158279.
24. Ihn H, Tamaki K. Competition analysis of the human α2(I) collagen promoter using synthetic oligonucleotides. J Invest Dermatol 2000, 114:1011-1016. 10.1046/j.1523-1747.2000.00956.x, 10771485.
25. Nakerakanti SS, Kapanadze B, Yamasaki M, Markiewicz M, Trojanowska M. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem 2006, 281:25259-25269. 10.1074/jbc.M600466200, 16829517.
26. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, Mohi MG. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115:3589-3597. 10.1182/blood-2009-04-215848, 2867267, 20197548.
27. Tamaki T, Ohnishi K, Hartl C, LeRoy EC, Trojanowska M. Characterization of a GC-rich region containing Sp1 binding site (s) as a constitutive responsive element of the α2(I) collagen gene in human fibroblasts. J Biol Chem 1995, 270:4299-4304. 10.1074/jbc.270.9.4299, 7876190.
28. Boast S, Su MW, Ramirez F, Sanchez M, Avvedimento EV. Functional analysis of cis-acting DNA sequences controlling transcription of the human type I collagen genes. J Biol Chem 1990, 265:13351-13356.
29. Asano Y, Czuwara J, Trojanowska M. Transforming growth factor-β regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 2007, 282:34672-34683. 10.1074/jbc.M703907200, 17884818.
30. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S. CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol 2008, 172:1650-1663. 10.2353/ajpath.2008.071049, 2408424, 18467694.
31. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K. Phosphatidylinositol 3-kinase is involved in α2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 2004, 172:7123-7135.
32. Czuwara-Ladykowska J, Shirasaki F, Jackers P, Watson DK, Trojanowska M. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem 2001, 276:20839-20848. 10.1074/jbc.M010133200, 11278621.
33. Bujor AM, Asano Y, Haines P, Lafyatis R, Trojanowska M. The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 2011, 63:1729-1737. 3381734, 21321929.
34. Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, Leof E, Varga J. A non-Smad mechanism of fibroblast activation by transforming growth factor-β via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009, 28:1285-1297. 10.1038/onc.2008.479, 19151753.
35. Jinnin M, Ihn H, Yamane K, Mimura Y, Asano Y, Tamaki K. α2(I) collagen gene regulation by protein kinase C signaling in human dermal fibroblasts. Nucleic Acids Res 2005, 33:1337-1351. 10.1093/nar/gki275, 552962, 15741186.
36. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, Silver RM, Jablonska S, Blaszczyk M, Watson DK, Trojanowska M. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 2003, 163:571-581. 10.1016/S0002-9440(10)63685-1, 1868228, 12875977.
37. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of TGF-β signaling in scleroderma fibroblasts. J Clin Invest 2004, 113:253-264. 10.1172/JCI16269, 310747, 14722617.
38. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M, Nakamura H. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994, 53:506-510. 1005389, 7944634.
39. Shi-Wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, Black CM, Abraham DJ. Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol 2001, 116:417-425. 10.1046/j.1523-1747.2001.01256.x, 11231316.
40. Soldano S, Montagna P, Villaggio B, Parodi A, Gianotti G, Sulli A, Seriolo B, Secchi ME, Cutolo M. Endothelin and sex hormones modulate the fibronectin synthesis by cultured human skin scleroderma fibroblasts. Ann Rheum Dis 2009, 68:599-602. 2651484, 18952637.
41. Asano Y, Markiewicz M, Kubo M, Szalai G, Watson DK, Trojanowska M. Transcription factor Fli1 regulates collagen fibrillogenesis in mouse skin. Mol Cell Biol 2009, 29:425-434. 10.1128/MCB.01278-08, 2612518, 19001092.
42. Schroll S, Arzt M, Sebah D, Nüchterlein M, Blumberg F, Pfeifer M. Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan. Respir Physiol Neurobiol 2010, 170:32-36. 10.1016/j.resp.2009.11.005, 19931426.
43. Mutsaers SE, Marshall RP, Goldsack NR, Laurent GJ, McAnulty RJ. Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 1998, 11:221-225. 10.1006/pupt.1998.0142, 9918760.
44. Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997, 156:600-608. 10.1164/ajrccm.156.2.9607123, 9279246.
45. van Giersbergen PL, Dingemanse J. Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjects. J Clin Pharmacol 2005, 45:42-47. 10.1177/0091270004270833, 15601804.
46. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum 2006, 54:2271-2279. 10.1002/art.21948, 16802366.
47. Guiducci S, Bellando Randone S, Bruni C, Carnesecchi G, Maresta A, Iannone F, Lapadula G, Matucci Cerinic M. Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 2012, 31:1723-1725. 10.1007/s10067-012-2074-5, 23053682.
48. Cambrey AD, Harrison NK, Dawes KE, Southcott AM, Black CM, du Bois RM, Laurent GJ, McAnulty RJ. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 1994, 11:439-445. 10.1165/ajrcmb.11.4.7917311, 7917311.
49. Yang Z, Krasnici N, Luscher TF. Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation 1999, 100:5-8. 10.1161/01.CIR.100.1.5, 10393673.
50. Iannone F, Riccardi MT, Guiducci S, Bizzoca R, Cinelli M, Matucci-Cerinic M, Lapadula G. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008, 67:1121-1126. 2564790, 18029384.
51. Abraham D. Role of endothelin in lung fibrosis. Eur Respir Rev 2008, 17:145-150.
52. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G, Watson DK, Trojanowska M. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 2010, 176:1983-1998. 10.2353/ajpath.2010.090593, 2843486, 20228226.
53. Tamaki Z, Asano Y, Hatano M, Yao A, Kawashima T, Tomita M, Kinugawa K, Nagai R, Sato S. Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases. Mod Rheumatol 2012, 22:94-99. 10.3109/s10165-011-0472-1, 21633912.
54. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 2008, 47:735-737. 10.1093/rheumatology/ken104, 18326532.
55. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011, 70:1003-1009. 3086082, 21398330.
56. Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Singh RR, Furst DE. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011, 63:3540-3546. 10.1002/art.30548, 3205223, 21769849.
57. Guo L, Chen XX, Gu YY, Zou HJ, Ye S. Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review. Clin Rheumatol 2012, 31:1395-1400. 10.1007/s10067-012-2032-2, 22875698.
58. Bournia VK, Evangelou K, Sfikakis PP. Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Semin Arthritis Rheum 2013, 42:377-390. 10.1016/j.semarthrit.2012.06.001, 22789835.
59. Soldano S, Montagna P, Brizzolara R, Ferrone C, Parodio A, Sulli A, Seriolo B, Villaggio B, Cutolo M. Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients. Reumatismo 2012, 64:326-334.